37 completed, 7 unknown, 2 recruiting, 1 not yet recruiting. 48 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Completed 37, Unknown 7, Recruiting 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 6 | Completed 6 |
Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye CAM-101, Vehicle Control - Dry Eye Disease, Dry Eye | Phase 3 | Not yet recruiting | Cambium Bio Limited | 475 | 2026-10-01 | 2026-06-12 |
| Phase III Study of OT202 in Treating Moderate to Severe Dry Eye OT202 conc 1%, Placebo - Dry Eye | Phase 3 | Recruiting | Ocumension Therapeutics (Suzhou) Co., Ltd | 842 | 2026-08-25 | 2026-10-15 |
| Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease SJP-0132, Placebo - Dry Eye | Phase 3 | Completed | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. | 427 | 2024-12-30 | 2025-11-26 |
| A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease tanfanercept, Vehicle - Dry Eye | Phase 3 | Suspended | HanAll BioPharma Co., Ltd. | 750 | 2024-05-01 | 2024-05-31 |
| Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users CycloSPORINE Ophthalmic, Intense Pulsed Light, Sham Intense Pulse Light - Dry Eye, Contact Lens Complication | Phase 3 | Unknown | Université de Sherbrooke | 44 | 2024-04-25 | 2024-05-01 |
| Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease VVN001 Ophthalmic Solution, 5%, VVN001 Ophthalmic Solution, Vehicle - Dry Eye | Phase 3 | Recruiting | VivaVision Biotech, Inc | 700 | 2024-04-01 | 2026-08-20 |
| Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye. recombinant human insulin, Autologous serum - Dry Eye, Sjogren Syndrome | Phase 3 | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | 25 | 2024-02-01 | 2026-08-27 |
| Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye Icross tear substitute, Hyabak tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 30 | 2023-11-01 | 2024-07-26 |
| Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients TJO-083, Diquafosol ophthalmic sodium solution 3% - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Taejoon Pharmaceutical Co., Ltd. | 271 | 2023-07-14 | 2025-04-22 |
| Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 124 | 2023-07-01 | 2024-06-27 |
| Platelet Rich Plasma in Corneal Surface Diseases Autologous platelet rich plasma eye drops - Persistent Corneal Epithelial Defects, Dry Eye | Phase 3 | Unknown | Assiut University | 70 | 2023-06-01 | 2023-02-27 |
| Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free - Dry Eye | Phase 3 | Completed | Research Insight LLC | 59 | 2022-06-03 | 2023-01-04 |
| Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) Oxervate, Vehicle - Dry Eye | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 104 | 2022-01-19 | 2024-06-07 |
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Palatin Technologies, Inc | 575 | 2021-12-30 | 2024-10-17 |
| A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye 0.25% Tanfanercept Ophthalmic Solution, Placebo - Dry Eye | Phase 3 | Completed | HanAll BioPharma Co., Ltd. | 260 | 2021-11-18 | 2023-10-23 |
| The Effect of a Novel Blueberry Supplement on Dry Eye Disease Blueberry gummy, Placebo gummy - Dry Eye | Phase 3 | Completed | SightSage Foods and Nutrition Inc. | 68 | 2021-09-09 | 2023-01-20 |
| Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK) OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray - Dry Eye | Phase 3 | Unknown | Brandon Baartman | 60 | 2021-08-30 | 2021-09-22 |
| The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 361 | 2021-08-28 | 2025-03-18 |
| ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease ALY688 Ophthalmic Solution - Dry Eye | Phase 2 / Phase 3 | Completed | Allysta Pharmaceutical | 922 | 2021-05-19 | 2023-03-16 |
| A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye HBM9036 0.25% Ophthalmic Solution, Placebo - Dry Eye | Phase 3 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 577 | 2021-02-25 | 2026-04-28 |
Showing 20 of 48. Sign in to see all of them.
Dry Eye Syndromes (48) · Sjogren's Syndrome (5) · Keratoconjunctivitis Sicca (4) · Conjunctival Diseases (2) · Corneal Diseases (2) · Autoimmune Diseases (1) · Disease (1) · Eye Diseases (1) · Insulin Resistance (1) · Keratitis (1) · Lacrimal Apparatus Diseases (1) · Meibomian Gland Dysfunction (1)
Eye Diseases (47) · Lacrimal Apparatus Diseases (47) · Arthritis (5) · Arthritis, Rheumatoid (5) · Connective Tissue Diseases (5) · Immune System Diseases (5) · Joint Diseases (5) · Mouth Diseases (5) · Musculoskeletal Diseases (5) · Rheumatic Diseases (5) · Salivary Gland Diseases (5) · Skin and Connective Tissue Diseases (5) · Stomatognathic Diseases (5) · Xerostomia (5) · Autoimmune Diseases (4)
Cyclosporins (2) · Ophthalmic Solutions (2) · Acupuncture Therapy (1) · Brimonidine Tartrate (1) · Carboxymethylcellulose Sodium (1) · Chondroitin (1) · Cyclosporine (1) · EBI-005 (1) · Fatty Acids, Omega-3 (1) · Fluorometholone (1) · Glycerol (1) · Hydroxychloroquine (1) · Intense Pulsed Light Therapy (1) · Loteprednol Etabonate (1) · Lubricant Eye Drops (1)
Aldeyra Therapeutics, Inc. (3) · HanAll BioPharma Co., Ltd. (3) · OmegaD LLC (2) · University of Seville (2) · Alcon Research (1) · Alexandria University (1) · Allergan (1) · Allysta Pharmaceutical (1) · Assiut University (1) · Brandon Baartman (1) · Cambium Bio Limited (1) · Dompé Farmaceutici S.p.A (1) · Eleven Biotherapeutics (1) · Eyegate Pharmaceuticals, Inc. (1) · Federal University of São Paulo (1)
United States (22) · China (6) · South Korea (3) · Spain (3) · Canada (2) · Japan (2) · Mexico (2) · Brazil (1) · Chile (1) · Egypt (1) · Italy (1)
Anat Galor, MD, MSPH (1) · Brandon Baartman, MD (1) · Brian Dodge (1) · Ehab Mossallam, PhD (1) · Eiji Murakami (1) · Eric Lortie-Milner, OD (1) · Flavio Mantelli, MD (1) · Gaafar Ragab (1) · Gail L Torkildsen, MD (1) · Guanghua Zhou (1) · Jialu Xia (1) · John Hovanesian, MD (1) · Karen Meerovitch, PhD (1) · Kazunori Omatsu (1)
PMID 11879137, PMID 14508260, PMID 15090417, PMID 15604871, PMID 16371776, PMID 17043506, PMID 17324465, PMID 18848318, PMID 20735287, PMID 21078194, PMID 21479340, PMID 21740369, PMID 22615787, PMID 22914501, PMID 22972393, PMID 26065354, PMID 26365210, PMID 27051257, PMID 27366013, PMID 27645318, PMID 28079022, PMID 28777385, PMID 29018685, PMID 29432648, PMID 29545413, PMID 29652551, PMID 29883769, PMID 29970389, PMID 30161055, PMID 31022469, PMID 31116166, PMID 31373862, PMID 31425752, PMID 31445751, PMID 31489258, PMID 32097181, PMID 32821497, PMID 33096271, PMID 33290317, PMID 33530719, PMID 33561944, PMID 34294637, PMID 36575626, PMID 36729473, PMID 37209594, PMID 38345056, PMID 38391283, PMID 39079754, PMID 41654845, PMID 42803882
U10EY022879 (1), U10EY022881 (1)